New Findings from Department of Biochemistry in the Area of Alzheimer Disease Reported (Circulating microRNAs as novel biomarkers of Alzheimer’s…

Drug Week

New Findings from Department of Biochemistry in the Area of Alzheimer Disease Reported (Circulating microRNAs as novel biomarkers of Alzheimer's disease)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Neurodegenerative Diseases and Conditions - Alzheimer Disease have been published. According to news reporting originating from Oran, Algeria, by NewsRx editors, the research stated, "Alzheimer's disease (AD) is the most common neurodegenerative disorder. Biomarkers could help identify patients at risk and define stages of this disease."

Our news editors obtained a quote from the research from the Department of Biochemistry, "Furthermore, biomarkers can be used to evaluate the efficiency of therapeutic agents under testing and thus accelerate the therapeutic discovery process. Biological exploration of AD is currently based on the measurement of beta amyloid peptides, tau and phospho-Tau proteins in cerebrospinal fluid. However, these tests have many limitations. So, the search for new biomarkers is very active. The ability of microRNAs (miRNAs) to regulate neuronal processes by acting as molecular switches in combination with their region specificity make that researchers are interested in miRNAs for their potential uses as biomarkers and as a treatment for neurodegenerative diseases including AD."

According to the news editors, the research concluded: "This literature review aims to take stock of the use of circulating miRNAs as a novel biomarkers for AD."

For more information on this research see: Circulating microRNAs as novel biomarkers of Alzheimer's disease. Clinica Chimica Acta, 2018;484():99-104. Clinica Chimica Acta can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Clinica Chimica Acta - www.journals.elsevier.com/clinica-chimica-acta/)

The news editors report that additional information may be obtained by contacting M. Zendjabil, Oran Univ Hosp, Dept. of Biochem, Oran, Algeria (see also Neurodegenerative Diseases and Conditions - Alzheimer Disease).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.cca.2018.05.039. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Oran, Algeria, Africa, Central Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions, Brain Diseases and Conditions, Diagnostics and Screening, Health and Medicine, Alzheimer Disease, Tauopathies, Biomarkers, Dementia, Department of Biochemistry.